NCT01462656View on ClinicalTrials.gov

Risk of Urinary Retention With Retigabine

TerminatedOBSERVATIONAL

Enrollment

1

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions

Epilepsy

Interventions

DRUG

Non-EZG containing AED polytherapy

AED polytherapy without EZG

DRUG

EZG containing AED polytherapy

AED polytherapy including EZG

DRUG

Non-EZG AED monotherapy

AED monotherapy without EZG

DRUG

EZG AED monotherapy

Any off-label use of EZG as monotherapy

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT01462656 - Risk of Urinary Retention With Retigabine | Biotech Hunter | Biotech Hunter